A proof-of-concept experiment involving a combined Alb-IFNβ pretreatment with a vaccinia CRT-E7 vaccine demonstrated an enhanced antitumor immune response and delayed tumor progression, suggesting a key role for the immunomodulation of Ly6Chi naive CD8+ T cells in this process. This evidence concerns the gene IFNB1 and neoplasm.